Major M&A deals impacting bioanalysis in 2026

With the second half of 2025 having picked up and ending with several strong mergers and acquisitions (M&A) deals, the life sciences sector enters 2026 with similar confidence. As always, therapeutic focus drives activity, with attention homing in on cardiometabolic, CNS, oncology and immunology areas. In this article, we review some of the largest deals so far, as well as forecasts for the rest of the year. Sanofi and Earendil agree on a bispecific antibodies deal Date: January 5, 2026 Value: Up to US $2.56 billion Impact: One of the earliest deals of 2026, the agreement aims to identify and develop...